Rituximab for recent type 1 diabetes in teens
Treatments studied
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This trial tests if repeated infusions of rituximab (a drug that calms the immune system) can help preserve insulin production in adolescents newly diagnosed with type 1 diabetes. It is for teens in Russia who started diabetes treatment within the last 4 months.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 12 and 17 and a half years old.
- Your diabetes was diagnosed less than 4 months ago.
- You must be a citizen of Russia.
- You weigh between 34 and 80 kg (depending on gender).
- Your body still makes some insulin (C-peptide level ≥ 200 pmol/L).
- You must not have active infections, tuberculosis, HIV, or hepatitis B/C.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination treatment for children who have been diagnosed with stage 1 type 1 diabetes, meaning they have some markers but do not yet need insulin. The treatment uses special immune cells (Treg cells) and an antibody (anti-CD20) to try to preserve the body's ability to make insulin.
This study tests whether teplizumab can help keep the body making insulin in people recently diagnosed with type 1 diabetes. It is for children and young adults aged 1 to 25, and compares the drug against a placebo.
This early-stage trial tests a combination approach to help your immune system stop attacking insulin-producing cells in newly diagnosed type 1 diabetes. It aims to preserve your body's ability to make insulin and slow disease progression.
This trial compares two medicines, teplizumab and ATG, to see if they can delay or prevent type 1 diabetes from progressing to needing insulin. It is for people ages 4 to 35 who have early signs of diabetes (stage 2) and specific autoantibodies.
This trial tests a new way to give a medicine called anti-thymocyte globulin (ATG) with or without verapamil, a blood pressure drug. It aims to slow down the loss of insulin-making cells in people newly diagnosed with type 1 diabetes.
This trial is testing a one-time cell treatment (CARC-101C) for people recently diagnosed with type 1 diabetes. The goal is to see if it is safe and can help preserve the body's ability to make some insulin.
Hear when a new Diabetes Mellitus, Type 1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.